Gregal (Tiotropium Bromide)

Gregal is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and as an add‑on therapy for asthma when other options are insufficient.

• Long‑term bronchodilation to improve airflow in patients with COPD.
• Reduction of COPD exacerbation frequency when used regularly.
• Adjunctive control of asthma symptoms in adults with persistent disease.
• Support for patients who require once‑daily dosing for convenience.
• May be considered in patients who cannot tolerate short‑acting bronchodilators.

The safety profile of Gregal includes both frequently observed and less common adverse events that clinicians monitor during therapy.

Common

• Dry mouth – a sensation of reduced saliva production often reported during the first weeks of therapy.
• Cough – transient irritation of the airway that may occur after inhalation or oral administration.
• Headache – mild to moderate head pain that can arise without a clear cause.

Serious

• Paradoxical bronchospasm – sudden narrowing of the airways that may worsen breathing difficulty.
• Severe allergic reaction (anaphylaxis) – rapid onset of hives, swelling, and respiratory distress requiring emergency care.
• Acute urinary retention – difficulty initiating urination that may need medical intervention.

Before prescribing Gregal, healthcare providers should evaluate patient history and consider specific safety considerations to minimize risk.

• Assess for known hypersensitivity to tiotropium bromide or other anticholinergic agents.
• Use caution in patients with narrow-angle glaucoma or a history of bladder obstruction.
• Monitor renal function, as impaired clearance may increase systemic exposure.
• Evaluate cardiovascular status, particularly in individuals with tachyarrhythmias.
• Avoid initiating therapy during acute COPD exacerbations without appropriate rescue medication.
• Discuss pregnancy and lactation status, noting that safety data are limited.

Gregal may interact with other medications; awareness of potential interactions helps ensure safe co‑administration.

Avoid

• Concomitant use with other anticholinergic drugs (e.g., ipratropium) may increase anticholinergic burden.
• Co‑administration with potent CYP3A4 inhibitors, although tiotropium is minimally metabolized, could alter plasma levels.

Use with caution

• Beta‑agonists (short‑acting or long‑acting) may require dose adjustments for optimal bronchodilation.
• Diuretics may exacerbate dry mouth; monitor patient comfort.
• Theophylline therapy should be monitored for additive respiratory effects.